Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial.

ABSTRACT:

Objectives

To explore candidate prognostic and predictive biomarkers identified in retrospective observational studies (interleukin-6, C-reactive protein, lactate dehydrogenase, ferritin, lymphocytes, monocytes, neutrophils, d-dimer, and platelets) in patients with coronavirus disease 2019 pneumonia after treatment with tocilizumab, an anti-interleukin-6 receptor antibody, using data from the COVACTA trial in patients hospitalized with severe coronavirus disease 2019 pneumonia.

Design

Exploratory analysis from a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial.

Setting

Hospitals in North America and Europe.

Patients

Adults hospitalized with severe coronavirus disease 2019 pneumonia receiving standard care.

Intervention

Randomly as

SUBMITTER: Tom J 

PROVIDER: S-EPMC8855771 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature